Alnylam Eyes Faster Drug Discovery With AI Partnership Worth Up To $2 Billion

Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) stock is up on Thursday after the company announced a strategic collaboration with Inceptive Nucleics, valued at up to $2 billion.

Benzinga • Jun 4, 2026

Alnylam Bets on AI for Speedy RNAi Drug Discovery and Development

ALNY teams up with Inceptive in a deal worth up to $2B, using AI models and proprietary RNAi data to speed drug discovery and improve candidate selection.

Zacks Investment Research • Jun 4, 2026

Alnylam, Inceptive sign up to $2 billion AI drug discovery deal

Alnylam Pharmaceuticals said on Wednesday it has teamed up with artificial-intelligence biotech ​Inceptive in a deal worth up ‌to $2 billion to use AI to speed up discovery of RNA-based medicines.

Reuters • Jun 3, 2026

Alnylam and Inceptive Form Strategic AI Collaboration to Accelerate the Discovery of RNAi Therapeutics

CAMBRIDGE, Mass. & PALO ALTO, Calif.--(BUSINESS WIRE)--Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, and Inceptive Nucleics, Inc., which builds foundation models of life, today announced a strategic collaboration agreement to increase the pace of therapeutic innovation. The collaboration is valued at up to $2B with upfront consideration of $30M, including cash and the purchase of Inceptive equity. Inceptive is eligible to receive additional payments based.

Business Wire • Jun 3, 2026

Alnylam Issues 2025 Corporate Responsibility Report

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, today announced the publication of its 2025 Corporate Responsibility Report. The 2025 report details how the company is scaling its corporate responsibility efforts in tandem with its business growth. Reflected throughout the report is the global theme, “Accepting Challenges to Improve the Health of Humanity,” which remains central to Alnylam's strategy and is embedded across.

Business Wire • May 19, 2026

Alnylam Pharmaceuticals Backs TTR Outlook as AMVUTTRA Access, Prescriber Growth Build

Alnylam Pharmaceuticals NASDAQ: ALNY Chief Financial Officer Jeff Poulton said the company remains confident in its TTR revenue guidance despite a slower first-quarter sequential growth rate, pointing to access, international launches and prescriber expansion as key drivers for the rest of the year.

MarketBeat • May 13, 2026

Alnylam Pharmaceuticals, Inc. (ALNY) Presents at Bank of America Global Healthcare Conference 2026 Transcript

Alnylam Pharmaceuticals, Inc. (ALNY) Presents at Bank of America Global Healthcare Conference 2026 Transcript

Seeking Alpha • May 13, 2026

New Data Analyses Presented at Heart Failure 2026 Demonstrate Robust and Consistent Clinical Benefit of Vutrisiran as a First-Line Treatment Option Across ATTR-CM Patient Populations, Including Patients with a High Disease Burden

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, today announced new analyses from the HELIOS-B Phase 3 study of vutrisiran in patients with the cardiomyopathy of wild-type or hereditary transthyretin-mediated amyloidosis (ATTR-CM), adding to the growing body of evidence supporting vutrisiran and reinforcing the durability of transthyretin (TTR) knockdown and its well-characterized safety profile. Vutrisiran is the first and.

Business Wire • May 12, 2026

Alnylam to Webcast Presentations at Upcoming Investor Conferences

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, announced today that management will present company overviews at the following upcoming investor conferences: BofA Securities Healthcare Conference on Wednesday, May 13, 2026, at 10:40 am PT (1:40 pm ET) in Las Vegas, Nevada Goldman Sachs Annual Healthcare Conference on Tuesday, June 9, 2026, at 11:20 am ET in Miami, Florida. A live audio webcast of each presentation will be.

Business Wire • May 7, 2026

Alnylam to Present New Analyses at Heart Failure 2026 Underscoring Consistent Clinical Profile of Vutrisiran in ATTR-CM

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, today announced it will present new data analyses for vutrisiran in patients with the cardiomyopathy of wild-type or hereditary transthyretin-mediated amyloidosis (ATTR-CM) at Heart Failure 2026, a scientific congress of the European Society of Cardiology, taking place May 9-12, 2026, in Barcelona, Spain. ATTR-CM is a heterogeneous and rapidly progressive disease, and patients.

Business Wire • May 4, 2026